There is growing evidence to suggest that reduced levels of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in adults is associated with an increased prevalence of NAFLD and progression to NASH or liver cirrhosis [7–9]. This evidence concerns the gene GH1 and metabolic dysfunction-associated steatohepatitis.